Julia Lier

Dr. Julia Lier

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2021 in Cells
Verified
Journal Article
Open access
PDF file
JLJulia Lier
Julia Lier
WSWolfgang J. Streit
Wolfgang J. Streit
IBIngo Bechmann
Ingo Bechmann
Classically, the following three morphological states of microglia have been defined: ramified, amoeboid and phagocytic. While ramified cells were long regarded as “resting”, amoeboid and phagocytic microglia were viewed as “activated”. In aged human brains, a fourth, morphologically novel state has been described, i.e., dystrophic microglia, which are thought to be senescent cells. Since microglia are not replenished by blood-borne mononuclear cells under physiological circumstances, they seem to have an “expiration date” limiting their capacity to phagocytose and support neurons. Identifying factors that drive microglial aging may thus be helpful to delay the onset of neurodegenerative diseases, such as Alzheimer’s disease (AD). Recent progress in single-cell deep sequencing methods allowed for more refined differentiation and revealed regional-, age- and sex-dependent differences of the microglial population, and a growing number of studies demonstrate various expression profiles defining microglial subpopulations. Given the heterogeneity of pathologic states in the central nervous system, the need for accurately describing microglial morphology and expression patterns becomes increasingly important. Here, we review commonly used microglial markers and their fluctuations in expression in health and disease, with a focus on IBA1 low/negative microglia, which can be found in individuals with liver disease.

27 September 2022 in Frontiers in Neurology
Verified
Journal Article
Open access
JLJulia Lier
Julia Lier
KSKristin Stoll
Kristin Stoll
HOHellmuth Obrig
Hellmuth Obrig
PBPaul Baum
Paul Baum
LDLea Deterding
Lea Deterding
DSDorothee Saur
Dorothee Saur
The post COVID-19 syndrome (PCS) is an emerging phenomenon worldwide with enormous socioeconomic impact. While many patients describe neuropsychiatric deficits, the symptoms are yet to be assessed and defined systematically. In this prospective cohort study, we report on the results of a neuropsychiatric consultation implemented in May 2021. A cohort of 105 consecutive patients with merely mild acute course of disease was identified by its high symptom load 6 months post infection using a standardized neurocognitive and psychiatric-psychosomatic assessment. In this cohort, we found a strong correlation between higher scores in questionnaires for fatigue (MFI-20), somatization (PHQ15) and depression (PHQ9) and worse functional outcome as measured by the post COVID functional scale (PCFS). In contrast, neurocognitive scales correlated with age, but not with PCFS. Standard laboratory and cardiopulmonary biomarkers did not differ between the group of patients with predominant neuropsychiatric symptoms and a control group of neuropsychiatrically unaffected PCS patients. Our study delineates a phenotype of PCS dominated by symptoms of fatigue, somatisation and depression. The strong association of psychiatric and psychosomatic symptoms with the PCFS warrants a systematic evaluation of psychosocial side effects of the pandemic itself and psychiatric comorbidities on the long-term outcome of patients with SARS-CoV-2 infection.

1 May 2019 in Brain Research
Verified
Journal Article
Closed access
JLJulia Lier
Julia Lier
KWKarsten Winter
Karsten Winter
JBJohannes Bleher
Johannes Bleher
JGJoachim Grammig
Joachim Grammig
WMWolf C. Mueller
Wolf C. Mueller
IBIngo Bechmann
Ingo Bechmann

19 March 2026 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Open access
PDF file
JLJulia Lier
Julia Lier
MPMarkus Ponleitner
Markus Ponleitner
DPDenny Popp
Denny Popp
LSLisa Schäfer
Lisa Schäfer
FKFranziska Küstermann
Franziska Küstermann
CBCaroline Bergner
Caroline Bergner
X‐linked adrenoleukodystrophy (X‐ALD) is a rare monogenic disorder characterized by marked variability in clinical presentation, age at onset, and disease progression. A deeper understanding of its natural history and the relationship between biochemical markers and clinical phenotypes is essential for improving disease monitoring, patient counseling, and optimizing clinical trial design. In particular, the predictive value of very long‐chain fatty acids (VLCFA) for clinical phenotypes has recently garnered increased attention. In this longitudinal, mixed prospective/retrospective, single‐center study, we analyzed clinical and biochemical data from 364 patients with X‐ALD (255 males). Parameters included clinical scores (EDSS, AACS), age at symptom onset, and disease manifestations, which were correlated with individual VLCFA levels. Patients with adrenal insufficiency (AI) exhibited significantly elevated VLCFA concentrations. Higher C26:0 levels were associated with faster progression (measured by EDSS); however, effect sizes were small and inter‐individual variability considerable. Although initial symptom severity was comparable between sexes, males presented earlier and progressed faster. Among patients seen in early clinical stages (EDSS ≤ 4.5), disease progression rates were higher (males: 0.34 ± 0.77; females: 0.11 ± 0.11) than in those presenting at more advanced stages (EDSS > 4.5; males: 0.23 ± 0.33; females: 0.09 ± 0.10). We provide comprehensive data on the prevalence of disease manifestations and the natural course of X‐ALD in a large adult cohort. The observed association between elevated VLCFA levels and adrenal insufficiency should be considered in future clinical monitoring and trial design. However, due to the small effect sizes and variability, VLCFA levels offer limited prognostic utility for individual patients.

1 January 2025 in Therapeutic Advances in Neurological Disorders
Verified
Journal Article
Open access
LSLisa Schäfer
Lisa Schäfer
AUAstrid Unterlauft
Astrid Unterlauft
BFBrit Froebrich-Andreß
Brit Froebrich-Andreß
CWCarolin Wollny
Carolin Wollny
MRMarie Rößler
Marie Rößler
WKWolfgang Köhler
Wolfgang Köhler
Background: People with rare diseases (RDs) often require intensive multidisciplinary care in disease-specific centers of excellence (CoE). However, access is limited for most patients living remotely. X-linked adrenoleukodystrophy (X-ALD) is a genetic RD leading to demyelination of the central and peripheral nervous system. Objectives: This randomized-controlled trial tested the feasibility, acceptance, and effectiveness of a multidisciplinary online intervention provided by a CoE on the quality of life (QoL) and well-being of symptomatic women with X-ALD. Design: Single-center, randomized-controlled clinical trial involving 68 German-speaking women with symptomatic X-ALD. Methods: Participants were randomized into an experimental group (EG, n = 34) receiving 12-month online intervention SMART-ALD and a waiting-list control group (WL-CG, n = 34) receiving 6-month SMART-ALD after a 6-month waiting period. Within SMART-ALD, participants were offered regular web-based neurological, social, psychological, and nutritional counseling and fitness training provided by the Leukodystrophy Outpatient Clinic at Leipzig, Germany. Group, time, and interaction effects on primary (self-reported QoL) and secondary (physical and mental health) outcomes after 6-month SMART-ALD were tested by repeated measures ANOVAs. Results: One WL-CG participant dropped out after the waiting period and was excluded from the final analysis. Significant QoL improvements in the EG versus WL-CG were found on self-reported mental health (mean difference (MD): 5.4, 95% confidence interval (CI) (2.8, 13.6), p = 0.020, η 2 = 0.08) and vitality (MD: 8.8, 95% CI (0.1, 17.4), p = 0.002, η 2 = 0.14). Further significant interaction effects emerged for improved knowledge about nutrition (MD: 0.4, 95% CI (−0.7, 1.4), p = 0.002, η 2 = 0.15), socio-medical benefits (MD: 1.8, 95% CI (0.5, 3.0), p = 0.033, η 2 = 0.07), and intense physical activity (MD: 2.2, 95% CI (−3.9, 8.4), p = 0.024, η 2 = 0.10). Conclusion: The study shows that easily accessible, multidisciplinary online interventions provided by the CoE have the potential to improve the QoL in people with RDs by providing regular access to specialized care. Trial registration: This study was registered on ClinicalTrials.gov ( https://clinicaltrials.gov/study/NCT04687007 ).

3 May 2023 in DGNeurologie
Verified
Journal Article
Closed access
PDF file
JLJulia Lier
Julia Lier
CBC.G. Bergner
C.G. Bergner
WKW. Köhler
W. Köhler